Jürgen R. Fischer - Concepedia

Author

Jürgen R. Fischer

Also Known As

Fischer, J., Fischer, J.R., J Fischer, J R Fischer, J. Fischer, J. R. Fischer, J.R Fischer, J.R. Fischer, Jurgen R. Fischer, Jürgen Fischer

111

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Löwenstein Medical (Germany)Heidelberg University German Center for Lung Research University Hospital Heidelberg German Cancer Research Center

About

Jürgen R. Fischer is an author at Löwenstein Medical (Germany) specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	33	1.7K
2	Health Sciences	3	3	115
3	Engineering	1	1	70
4	Natural Sciences	1	1	26
5	Allergy	1	1	49

Jürgen R. Fischer

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures Harald Lahm, Sabine André, Andreas Hoeflich, Journal of Cancer Research and Clinical Oncology Comprehensive Galectin FingerprintingTherapeutic ProceduresMedicineProteomicsHistopathology	2001	209
Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells Marlon R. Schneider, Andreas Hoeflich, Jürgen R. Fischer, Cancer Letters InflammationCytokineMedicineImmunologyColorectal Cancer	2000	159
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer David Planchard, Niels Reinmuth, Jürgen R. Fischer, Annals of Oncology	2020	156
Blockade of the insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF‐II‐mediated autocrine loop Harald Lahm, Paul Amstad, Josiane Wyniger, International Journal of Cancer	1994	144
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study Luis Paz‐Ares, J. Mezger, Tudor–Eliade Ciuleanu, The Lancet Oncology First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCancer Treatment	2015	129
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study David Planchard, Takashi Yokoi, Michael McCleod, Clinical Lung Cancer	2016	129
<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non‐small cell lung cancer Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, International Journal of Cancer	2018	119
Identification of a highly lethal V3<sup>+</sup>TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma Petros Christopoulos, Martina Kirchner, Farastuk Bozorgmehr, International Journal of Cancer	2018	103
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases Anna‐Lena Volckmar, Jonas Leichsenring, Martina Kirchner, International Journal of Cancer	2019	100
Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma Jürgen R. Fischer, U. Ohnmacht, Norman Rieger, Lung Cancer Malignant DiseaseMalignant MesotheliomaMedicinePathologyCancer Genomics	2006	94

Page 1